Clinical Read2026-10-24

Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)

Immatics N.V.IMTX
Indication
Melanoma
Stage
phase1
Event
Interim Data
Details

July 17, 2026: Immatics N.V. (NASDAQ: IMTX) announced it will present three datasets at ESMO Congress 2026 (Oct 23–27, 2026; Madrid), spanning its PRAME-directed cell therapy and bispecific programs.

  • anzu-cel (anzutresgene autoleucel; IMA203) PRAME TCR T-cell therapy: Phase 1b poster in advanced/metastatic cutaneous and uveal melanoma focused on predictors of durable response (Poster 2128P; Oct 24, 2026, 12:00–12:45 CET).

  • IMA203CD8 PRAME cell therapy: Phase 1 proffered paper (oral) across multiple PRAME-positive solid tumors, including durability follow-up at clinically relevant dose levels in gynecologic cancers (Presentation 1946O; Oct 23, 2026, 13:30–15:00 CET).

  • IMA402 PRAME bispecific (TCER): Phase 1b rapid oral covering data at the recommended Phase 2 dose (RP2D) range across multiple cancers, supporting continued development in expansion cohorts and combination approaches (Presentation 1955RO; Oct 24, 2026, 08:30–10:00 CET).

Full ESMO abstracts are scheduled to be published October 19, 2026 (00:05 CEST).